10-Q quarterly report · filed Nov 3, 2026

Emergent BioSolutions Inc. (EBS) Q3 2026 10-Q Quarterly Report

Short answer

Emergent BioSolutions Inc. (EBS) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $110M (down 52.4% year over year) with net income of −$33M.

Q3 2026 key financials · XBRL

Revenue
$110M
−52.4% YoY · −53.1% QoQ
Net income
−$33M
−163.9% YoY · +81.9% QoQ
Operating margin
-33.9%
EPS (diluted)
−$0.64
−171.1% YoY · +81.3% QoQ

Source: XBRL data from the Emergent BioSolutions Inc. (EBS) Q3 2026 10-Q on SEC EDGAR. USD.

Emergent BioSolutions Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $110.0M, down 52% YoY from $231.1M
  • Gross margin 14% vs 54% YoY, operating loss $37.3M vs income $76.5M
  • Best segment Anthrax MCM, revenue $25.1M, up $23.7M; worst Smallpox MCM, $26.7M, down 68%
  • Cash and equivalents $175.7M vs $205.4M at December 31; operating cash flow $122.4M
  • Debt repurchases $75.0M principal, $68.1M cash; management expects continued quarterly variability and cites NARCAN pricing and volume pressure

Risk Factors

  • Third-party manufacturing: FDA noncompliance could halt sole-source production and interrupt customer supply
  • NARCAN competition: Teva, Padagis and Amneal generics could erode sales through lower-priced or free alternatives
  • Restructuring plan: August 5, 2026 workforce reductions and wet-laboratory closures may disrupt operations
  • Political and social pressures: USG preference for U.S.-made products may reduce Winnipeg facility purchases
  • Restructuring compliance: Workforce reductions may trigger wrongful-termination or discrimination claims under local labor laws

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Emergent BioSolutions Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.